Logo image of TARS

TARSUS PHARMACEUTICALS INC (TARS) Stock Fundamental Analysis

NASDAQ:TARS - Nasdaq - US87650L1035 - Common Stock - Currency: USD

42.5  +1.21 (+2.93%)

Fundamental Rating

3

Taking everything into account, TARS scores 3 out of 10 in our fundamental rating. TARS was compared to 193 industry peers in the Pharmaceuticals industry. TARS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TARS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TARS has reported negative net income.
In the past year TARS has reported a negative cash flow from operations.
In the past 5 years TARS always reported negative net income.
TARS had negative operating cash flow in 4 of the past 5 years.
TARS Yearly Net Income VS EBIT VS OCF VS FCFTARS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

With a Return On Assets value of -35.70%, TARS perfoms like the industry average, outperforming 46.20% of the companies in the same industry.
TARS's Return On Equity of -56.57% is in line compared to the rest of the industry. TARS outperforms 54.89% of its industry peers.
Industry RankSector Rank
ROA -35.7%
ROE -56.57%
ROIC N/A
ROA(3y)-28.72%
ROA(5y)-21.95%
ROE(3y)-36.49%
ROE(5y)-26.75%
ROIC(3y)N/A
ROIC(5y)N/A
TARS Yearly ROA, ROE, ROICTARS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

With an excellent Gross Margin value of 92.97%, TARS belongs to the best of the industry, outperforming 96.74% of the companies in the same industry.
TARS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TARS Yearly Profit, Operating, Gross MarginsTARS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

TARS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TARS has more shares outstanding
Compared to 5 years ago, TARS has more shares outstanding
Compared to 1 year ago, TARS has a worse debt to assets ratio.
TARS Yearly Shares OutstandingTARS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M
TARS Yearly Total Debt VS Total AssetsTARS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 5.61 indicates that TARS is not in any danger for bankruptcy at the moment.
TARS's Altman-Z score of 5.61 is amongst the best of the industry. TARS outperforms 82.07% of its industry peers.
A Debt/Equity ratio of 0.30 indicates that TARS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.30, TARS is doing worse than 60.87% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Altman-Z 5.61
ROIC/WACCN/A
WACC9.85%
TARS Yearly LT Debt VS Equity VS FCFTARS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M

2.3 Liquidity

TARS has a Current Ratio of 5.42. This indicates that TARS is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.42, TARS is doing good in the industry, outperforming 66.85% of the companies in the same industry.
TARS has a Quick Ratio of 5.38. This indicates that TARS is financially healthy and has no problem in meeting its short term obligations.
TARS has a Quick ratio of 5.38. This is in the better half of the industry: TARS outperforms 68.48% of its industry peers.
Industry RankSector Rank
Current Ratio 5.42
Quick Ratio 5.38
TARS Yearly Current Assets VS Current LiabilitesTARS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

TARS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.19%, which is quite impressive.
The Revenue for TARS has decreased by -32.43% in the past year. This is quite bad
EPS 1Y (TTM)33.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.2%
Revenue 1Y (TTM)-32.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%407.88%

3.2 Future

TARS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.25% yearly.
TARS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 142.78% yearly.
EPS Next Y29.25%
EPS Next 2Y26.02%
EPS Next 3Y34.4%
EPS Next 5Y19.25%
Revenue Next Year1671.91%
Revenue Next 2Y474.49%
Revenue Next 3Y269.8%
Revenue Next 5Y142.79%

3.3 Evolution

TARS Yearly Revenue VS EstimatesTARS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TARS Yearly EPS VS EstimatesTARS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TARS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TARS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TARS Price Earnings VS Forward Price EarningsTARS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TARS Per share dataTARS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

TARS's earnings are expected to grow with 34.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.02%
EPS Next 3Y34.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TARS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TARSUS PHARMACEUTICALS INC

NASDAQ:TARS (2/26/2025, 12:36:58 PM)

42.5

+1.21 (+2.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-17 2025-03-17/amc
Inst Owners102.92%
Inst Owner Change-88.41%
Ins Owners3.37%
Ins Owner Change-0.05%
Market Cap1.62B
Analysts86.67
Price Target68.72 (61.69%)
Short Float %23.11%
Short Ratio12.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.56%
Min EPS beat(2)6.62%
Max EPS beat(2)38.51%
EPS beat(4)4
Avg EPS beat(4)17.17%
Min EPS beat(4)5.75%
Max EPS beat(4)38.51%
EPS beat(8)7
Avg EPS beat(8)13.69%
EPS beat(12)10
Avg EPS beat(12)15.28%
EPS beat(16)12
Avg EPS beat(16)28.16%
Revenue beat(2)2
Avg Revenue beat(2)17.49%
Min Revenue beat(2)8.6%
Max Revenue beat(2)26.37%
Revenue beat(4)4
Avg Revenue beat(4)54.09%
Min Revenue beat(4)8.6%
Max Revenue beat(4)126.31%
Revenue beat(8)5
Avg Revenue beat(8)56.45%
Revenue beat(12)6
Avg Revenue beat(12)16.37%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.65%
PT rev (3m)3.65%
EPS NQ rev (1m)4.02%
EPS NQ rev (3m)15.44%
EPS NY rev (1m)0.72%
EPS NY rev (3m)15.25%
Revenue NQ rev (1m)2.6%
Revenue NQ rev (3m)29.79%
Revenue NY rev (1m)0.39%
Revenue NY rev (3m)7.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.53
P/FCF N/A
P/OCF N/A
P/B 6.84
P/tB 7.1
EV/EBITDA N/A
EPS(TTM)-3.1
EYN/A
EPS(NY)-1.91
Fwd EYN/A
FCF(TTM)-2.66
FCFYN/A
OCF(TTM)-2.62
OCFYN/A
SpS3.39
BVpS6.21
TBVpS5.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.7%
ROE -56.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.97%
FCFM N/A
ROA(3y)-28.72%
ROA(5y)-21.95%
ROE(3y)-36.49%
ROE(5y)-26.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 131.32%
Cap/Sales 1.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.42
Quick Ratio 5.38
Altman-Z 5.61
F-Score3
WACC9.85%
ROIC/WACCN/A
Cap/Depr(3y)324.08%
Cap/Depr(5y)376.45%
Cap/Sales(3y)11.52%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.2%
EPS Next Y29.25%
EPS Next 2Y26.02%
EPS Next 3Y34.4%
EPS Next 5Y19.25%
Revenue 1Y (TTM)-32.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%407.88%
Revenue Next Year1671.91%
Revenue Next 2Y474.49%
Revenue Next 3Y269.8%
Revenue Next 5Y142.79%
EBIT growth 1Y-23.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.18%
EBIT Next 3Y31.58%
EBIT Next 5Y21.31%
FCF growth 1Y-99.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-99.24%
OCF growth 3YN/A
OCF growth 5YN/A